Related Experiment Video
Updated: May 15, 2026

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration
Published on: June 9, 2023
PI3K inhibition enhances doxorubicin-induced apoptosis in sarcoma cells
Diana Marklein1, Ulrike Graab, Ivonne Naumann
1Institute of Human Genetics, University Medical Center, Goettingen, Germany.
Abstract:
We searched for a drug capable of sensitization of sarcoma cells to doxorubicin (DOX). We report that the dual PI3K/mTOR inhibitor PI103 enhances the efficacy of DOX in several sarcoma cell lines and interacts with DOX in the induction of apoptosis. PI103 decreased the expression of MDR1 and MRP1, which resulted in DOX accumulation. However, the enhancement of DOX-induced apoptosis was unrelated to DOX accumulation. Neither did it involve inhibition of mTOR. Instead, the combination treatment of DOX plus PI103 activated Bax, the mitochondrial apoptosis pathway, and caspase 3. Caspase 3 activation was also observed in xenografts of sarcoma cells in nude mice upon combination of DOX with the specific PI3K inhibitor GDC-0941. Although the increase in apoptosis did not further impact on tumor growth when compared to the efficient growth inhibition by GDC-0941 alone, these findings suggest that inhibition of PI3K may improve DOX-induced proapoptotic effects in sarcoma. Taken together with similar recent studies of neuroblastoma- and glioblastoma-derived cells, PI3K inhibition seems to be a more general option to sensitize tumor cells to anthracyclines.
Insights
The dual PI3K/mTOR inhibitor PI103 enhances doxorubicin (DOX) efficacy in sarcoma by activating apoptosis pathways. PI3K inhibition shows promise for sensitizing tumor cells to anthracyclines like DOX.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Sarcoma treatment often involves chemotherapy, but resistance can limit efficacy.
- Doxorubicin (DOX) is a common anthracycline chemotherapy agent.
- Identifying agents to overcome drug resistance and enhance chemotherapy effectiveness is crucial.
Purpose of the Study:
- To identify a drug that sensitizes sarcoma cells to doxorubicin (DOX).
- To investigate the mechanism by which this sensitization occurs.
- To evaluate the potential of PI3K inhibition as a general strategy to enhance anthracycline efficacy.
Main Methods:
- Screening for drugs that enhance DOX efficacy in sarcoma cell lines.
- Assessing the effects of PI103 and DOX combination on apoptosis induction.
- Measuring the expression of drug resistance markers (MDR1, MRP1).
- Analyzing the activation of apoptotic pathways (Bax, mitochondrial pathway, caspase 3).
- Evaluating combination therapy in sarcoma xenograft models in mice.
Main Results:
- The dual PI3K/mTOR inhibitor PI103 enhanced DOX efficacy in multiple sarcoma cell lines.
- PI103 decreased MDR1 and MRP1 expression, leading to increased DOX accumulation.
- Enhanced apoptosis was independent of DOX accumulation and mTOR inhibition.
- Combination treatment activated the mitochondrial apoptosis pathway, Bax, and caspase 3.
- Caspase 3 activation was observed in vivo with a PI3K inhibitor (GDC-0941) and DOX.
Conclusions:
- PI3K inhibition, exemplified by PI103 and GDC-0941, enhances DOX-induced apoptosis in sarcoma.
- The pro-apoptotic effect is mediated through the activation of Bax, mitochondrial pathway, and caspase 3.
- PI3K inhibition represents a potential general strategy to sensitize various tumor cells, including neuroblastoma and glioblastoma, to anthracyclines.
Related Concept Videos
PI3K/mTOR/AKT Signaling Pathway
Inhibition of Cdk Activity
Abnormal Proliferation